TD Cowen analyst Ritu Baral has maintained their bullish stance on NGNE stock, giving a Buy rating on May 9.
Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Ritu Baral’s rating is based on several promising developments within Neurogene’s pipeline, particularly the ongoing progress in their Rett syndrome program. The expansion of the age range in the Phase 1/2 trial and the upcoming interim data expected in the second half of 2025 demonstrate the company’s commitment to advancing their clinical trials and potentially addressing significant unmet medical needs.
Additionally, Neurogene’s financial position appears robust, with a cash runway projected to extend into the second half of 2027. This financial stability supports the company’s ability to continue its research and development activities without immediate financial constraints. Despite potential challenges with regulatory timelines due to external factors, the inclusion of their program in the FDA’s START initiative may facilitate timely communications and updates, further supporting the Buy rating.
Based on the recent corporate insider activity of 8 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of NGNE in relation to earlier this year.